Wegovy Pricing at a Glance: Every Pathway
without insurance
at retail pharmacy
Novo Nordisk direct program
no insurance needed
same active ingredient
all consultations + shipping
The right question is not just "how much does Wegovy cost?" but "which pathway is most affordable for your specific situation?" The answer varies significantly depending on your insurance status. For commercially insured patients whose plans cover Wegovy and who can obtain prior authorization, the NovoCare savings card can reduce out-of-pocket to approximately $25/month — dramatically less than any alternative. For cash-pay patients without usable coverage, Wegovy's retail cost of ~$1,349/month is unsustainable for most patients, and alternatives become essential.
Wegovy Pricing by Dose: Why It's Flat Across All Tiers
One distinctive aspect of Wegovy's pricing structure is that the retail list price is essentially flat across all dose tiers. Unlike compounded alternatives (which charge more for higher doses because they contain more active ingredient) or other medications that scale with dose, Wegovy's auto-injector pen is priced at a consistent monthly rate regardless of whether the pen contains 0.25 mg or 2.4 mg of semaglutide.
Wegovy Monthly Cost by Dose — Retail vs. Compounded Alternative
| Dose | Treatment Phase | Wegovy Retail | Luma Health (Compounded) |
|---|---|---|---|
| 0.25 mg/week | Starting (weeks 1–4) | ~$1,349/mo | $197/mo |
| 0.5 mg/week | Titration (weeks 5–8) | ~$1,349/mo | $197/mo |
| 1.0 mg/week | Titration (weeks 9–12) | ~$1,349/mo | $197/mo |
| 1.7 mg/week | Titration (weeks 13–16) | ~$1,349/mo | $197/mo |
| 2.4 mg/week | Maintenance (ongoing) | ~$1,349/mo | $197/mo |
The flat pricing structure means that at the starting 0.25 mg dose — which contains a small fraction of the active ingredient of the maintenance dose — patients using Wegovy pay the same $1,349/month they will pay at maintenance. Compounded semaglutide from Luma Health also uses flat pricing, but at $197/month across every dose tier from 0.25 mg to 2.4 mg.
Every Wegovy Cost Pathway Explained
★ NovoCare Savings Card (commercial insurance) Best for insured patients
The Novo Nordisk NovoCare savings card can reduce out-of-pocket Wegovy cost to approximately $25/month for commercially insured patients whose plan covers Wegovy and who receive prior authorization. This is the lowest possible cost for brand-name Wegovy and the most cost-effective option overall when available. Critical eligibility requirements: you must have active commercial insurance that covers Wegovy, Medicare, Medicaid, and TRICARE patients are typically not eligible. You must receive prior authorization from your insurance plan. Income caps and benefit maximums apply. The savings card is not a guaranteed benefit — it is a copay-assistance program contingent on insurance approval.
WegovyDirect — Cash-Pay Without Insurance Better cash-pay option than retail
Novo Nordisk's WegovyDirect program offers brand-name Wegovy directly to cash-pay patients at approximately $499/month — a significant reduction from the $1,349/month retail list price, though still substantially more than compounded alternatives. WegovyDirect is available to patients without insurance or with insurance that doesn't cover Wegovy. The $499/month price applies across dose tiers (flat pricing, as with retail). For patients who specifically want brand-name Wegovy over compounded semaglutide, WegovyDirect is the most affordable brand-name pathway. Verify current pricing and availability at wegovy.com.
Retail Pharmacy (Walgreens, CVS, Costco, etc.) — Without Insurance Most expensive pathway
Brand-name Wegovy at retail pharmacies without insurance ranges from approximately $1,300 to $1,400/month depending on the pharmacy and location. GoodRx and similar coupon services can reduce this by approximately 10 to 20% — bringing the best available price to roughly $1,050 to $1,200/month. At this price, a 12-month treatment course costs $12,600 to $16,188. For most patients without usable insurance, retail pharmacy Wegovy is not financially sustainable for the 12 to 24+ months required for meaningful and maintained weight loss results.
NovoCare Patient Assistance (income-based) Limited eligibility
Novo Nordisk operates a patient assistance program for uninsured, lower-income patients who meet specific income thresholds and have no prescription drug coverage. For eligible patients, the program can provide Wegovy at no or minimal cost. The program requires an application process, income documentation, and does not cover patients with Medicare, Medicaid, or any prescription drug coverage. Income eligibility thresholds are strict. Verify current program terms and eligibility at novocare.com — program availability and terms can change.
★ Compounded Semaglutide (Luma Health) — Cash-Pay Best value for most cash-pay patients
Compounded semaglutide through a licensed telehealth provider like Luma Health delivers the same active pharmaceutical ingredient as Wegovy — semaglutide — at $197/month flat, prepared by VialsRX (Texas State Board of Pharmacy #35264). No insurance required, no prior authorization, no savings card enrollment process. The same pharmacological mechanism as Wegovy, the same expected outcomes at equivalent doses, at 85% less than Wegovy retail and 60% less than WegovyDirect. For the majority of patients who cannot access the NovoCare savings card ($25/mo) due to insurance status, compounded semaglutide is the most financially accessible legitimate pathway to semaglutide treatment.
The Insurance Coverage Reality for Wegovy in 2026
Why Insurance Often Doesn't Solve the Wegovy Affordability Problem
The 12-Month Cost Math: Wegovy vs. Compounded Semaglutide
Wegovy — 12-Month Scenarios
★ Luma Health — 12 Months (Flat)
Wegovy vs. Compounded Semaglutide: Full Comparison
| Factor | Wegovy (Brand-Name) | Luma Health (Compounded Sema) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (identical molecule) |
| FDA status | ✓ FDA-approved finished product | Compounded per prescription (active ingredient FDA-approved) |
| Max dose available | 2.4 mg/week | ✓ Up to 2.4 mg/week |
| Retail cash-pay price | ~$1,349/mo | $197/mo flat |
| Best cash-pay option | WegovyDirect ~$499/mo | $197/mo — always |
| Best insured option | ~$25/mo (NovoCare + prior auth) | $197/mo (no insurance needed) |
| Insurance required | Yes (for savings card) | ✓ No |
| Prior authorization | Required for coverage | ✓ None required |
| Delivery device | Auto-injector pen (Novo Nordisk) | Multi-dose vial + syringe |
| Annual cost (cash-pay) | ~$16,188 (retail) / ~$5,988 (WegovyDirect) | $2,364 (flat) |
| Prescribing + medication | Separate (need external provider) | ✓ Included — Wasef Health, PC |
| Pharmacy verifiable | Licensed retail pharmacy | ✓ VialsRX, TX #35264, verifiable |
Frequently Asked Questions
How much does Wegovy cost per month without insurance in 2026?
Wegovy's retail list price without insurance is approximately $1,349 per month in 2026. This flat price applies across all dose tiers from the 0.25 mg/week starting dose through the 2.4 mg/week maintenance dose. GoodRx and similar discount cards can reduce the retail price by approximately 10 to 20%, bringing the best available cash price to approximately $1,050 to $1,200/month. Novo Nordisk's WegovyDirect program offers brand-name Wegovy directly at approximately $499/month for cash-pay patients. Compounded semaglutide through Luma Health (same active ingredient) is available at $197/month flat. Verify current Wegovy pricing directly at wegovy.com and novocare.com, as pricing can change.
Does the Wegovy savings card bring the cost to $25/month?
For eligible patients, yes — but the eligibility requirements are strict. The NovoCare savings card typically reduces out-of-pocket Wegovy cost to approximately $25/month for commercially insured patients whose insurance plan covers Wegovy and who have received prior authorization. The savings card does not apply to Medicare Part D beneficiaries, Medicaid patients, or patients without commercial insurance. Prior authorization must be approved before the savings card reduces cost — the card helps with the patient's copay, not with uncovered claims. Patients who cannot access the savings card due to insurance status should evaluate WegovyDirect ($499/month) or compounded semaglutide ($197/month) as alternatives.
What is WegovyDirect and how much does it cost?
WegovyDirect is Novo Nordisk's direct-to-patient cash-pay program for Wegovy, typically priced at approximately $499/month — a substantial reduction from the $1,349/month retail list price but still more than compounded alternatives. WegovyDirect is available to patients without insurance or with insurance that doesn't cover Wegovy, and does not require prior authorization. The program provides brand-name Wegovy in the standard auto-injector pen format. For patients who specifically want brand-name Wegovy (not compounded semaglutide) and are paying cash, WegovyDirect is the most affordable brand-name pathway. Verify current WegovyDirect pricing and availability at wegovy.com.
Is compounded semaglutide the same as Wegovy?
Compounded semaglutide contains the same active pharmaceutical molecule as Wegovy — semaglutide — at the same therapeutic doses. The pharmacological mechanism (GLP-1 receptor activation), expected clinical outcomes (average 14.9% weight loss at 2.4 mg/week in STEP 1), and side effect profile are determined by the active molecule, not by the manufacturer. Differences between Wegovy and compounded semaglutide: Wegovy is an FDA-approved finished drug product from Novo Nordisk, delivered in a proprietary auto-injector pen, with the full regulatory assurance of an FDA drug approval. Compounded semaglutide is prepared per individual prescription by a licensed 503A sterile compounding pharmacy, delivered in a multi-dose vial, and is not itself FDA-approved as a finished drug product. For cash-pay patients, the cost difference ($197/mo vs. $1,349/mo) represents the elimination of brand manufacturing costs, pen engineering, and distribution premiums.
Does Medicare cover Wegovy for weight loss?
As of June 2026, traditional Medicare Part D does not cover GLP-1 medications prescribed solely for chronic weight management. Medicare patients who need semaglutide specifically for type 2 diabetes may be able to access Ozempic (the diabetes-indicated semaglutide product) through Medicare Part D coverage. Medicare Advantage plans vary — some have begun to include weight management medications, but coverage is plan-specific and not universal. Medicare patients who cannot access coverage for Wegovy and want semaglutide for weight management should evaluate cash-pay options, including WegovyDirect ($499/month) and compounded semaglutide ($197/month through Luma Health) — both of which are available without insurance.
How does Wegovy compare to Ozempic in cost?
Wegovy and Ozempic both contain semaglutide but are approved for different indications and at different doses. Wegovy is FDA-approved for chronic weight management at up to 2.4 mg/week. Ozempic is FDA-approved for type 2 diabetes at up to 2.0 mg/week. At retail, Ozempic is typically less expensive than Wegovy — approximately $900 to $998/month vs. $1,349/month for Wegovy. The savings card programs differ: the Ozempic savings card is designed for T2D patients with commercial insurance, while the NovoCare Wegovy savings card targets weight management patients. Patients seeking semaglutide for weight loss are clinically better served by Wegovy (higher maximum dose, weight management indication) or compounded semaglutide (same molecule, up to 2.4 mg/week, dramatically lower cost).
Can I get Wegovy covered by insurance?
Yes, but coverage is not universal. Wegovy coverage through commercial insurance has become more common but requires prior authorization in virtually all cases where it is covered. Coverage rates and approval rates vary significantly by employer plan, insurance carrier, and patient medical profile. To pursue Wegovy coverage: (1) check your plan's formulary specifically for Wegovy by name; (2) if covered, request prior authorization from your prescribing provider; (3) if approved, apply the NovoCare savings card at your pharmacy. If your plan excludes Wegovy, consider a formal appeal with supporting clinical documentation, or evaluate compounded semaglutide as a cash-pay alternative during the appeals process.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- FDA. Wegovy (semaglutide) Prescribing Information. FDA.gov
- NovoCare. Wegovy Price Guide. novocare.com
- Novo Nordisk. WegovyDirect Program. wegovy.com
- CMS. Medicare Coverage of Weight Loss Medications. cms.gov
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov